DexCom, Inc. (DXCM) EV/EBITDA Ratio: 20.28x
Is DexCom, Inc.’s EV/EBITDA ratio high or low?
DexCom, Inc.'s EV/EBITDA ratio of 20.28x is 71% below its 5-year average of 70.63x, near the low end of its 5-year range (15.60x–160.45x).
As of Sunday, June 14, 2026. 19.89% below its 12-month average of 25.32x.
DXCM EV/EBITDA Ratio Chart
DXCM Average EV/EBITDA Ratio Chart
DXCM Current vs Average EV/EBITDA Ratio Chart
DXCM EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
20.28x
EV/EBITDA RATIO AVG TTM
25.32x
EV/EBITDA RATIO AVG 3Y
42.50x
EV/EBITDA RATIO AVG 5Y
70.63x
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-19.89%
CURRENT VS 3Y AVG
-52.28%
CURRENT VS 5Y AVG
-71.29%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
DXCM Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $29.08B | 20.28x | 25.32x | 42.50x | 70.63x |
| Biogen Inc. (BIIB)vs › | $29.53B | 12.16x | 8.71x | 11.20x | 12.24x |
| IQVIA Holdings Inc. (IQV)vs › | $30.29B | 12.77x | 13.60x | 15.11x | 17.15x |
| Medline Inc. (MDLN)vs › | $30.96B | 14.87x | 16.18x | 16.18x | 16.18x |
| Centene Corporation (CNC)vs › | $32.19B | N/A | 4.99x | 7.28x | 9.49x |
| Veeva Systems Inc. (VEEV)vs › | $25.92B | 19.17x | 33.23x | 43.96x | 53.99x |
| Zoetis Inc. (ZTS)vs › | $33.36B | 10.15x | 15.60x | 20.66x | 23.73x |
| Waters Corporation (WAT)vs › | $23.17B | 37.11x | 21.72x | 21.28x | 21.47x |
| United Therapeutics Corporation (UTHR)vs › | $23.17B | 14.41x | 11.89x | 10.20x | 11.38x |
| BioNTech SE (BNTX)vs › | $22.90B | N/A | 51.40x | 19.63x | 20.05x |
EV/EBITDA vs. its own history
At 20.3, EV/EBITDA is cheaper than usual, sitting higher than 4% of its 8-year history.
8-year low
15.6
median
94.5
8-year high
2829.2
DexCom, Inc. EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for DexCom, Inc. (DXCM)?
- The EV/EBITDA ratio for DXCM stock is 20.28x.
- Is DexCom, Inc.'s EV/EBITDA ratio high or low?
- DexCom, Inc.'s EV/EBITDA ratio of 20.28x is 71% below its 5-year average of 70.63x, near the low end of its 5-year range (15.60x–160.45x).
- What is the TTM average EV/EBITDA ratio for DexCom, Inc. (DXCM)?
- The TTM average EV/EBITDA ratio for DXCM stock is 25.32x.
- What is the 3Y average EV/EBITDA ratio for DexCom, Inc. (DXCM)?
- The 3Y average EV/EBITDA ratio for DXCM stock is 42.50x.
- What is the 5Y average EV/EBITDA ratio for DexCom, Inc. (DXCM)?
- The 5Y average EV/EBITDA ratio for DXCM stock is 70.63x.
DexCom, Inc. EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-12 | 20.28x |
| 2026-06-11 | 20.25x |
| 2026-06-10 | 20.12x |
| 2026-06-09 | 21.03x |
| 2026-06-08 | 20.61x |
| 2026-06-05 | 19.61x |
| 2026-06-04 | 19.54x |
| 2026-06-03 | 19.58x |
| 2026-06-02 | 19.77x |
| 2026-06-01 | 20.14x |
| 2026-05-29 | 19.84x |
| 2026-05-28 | 19.47x |
| 2026-05-27 | 18.92x |
| 2026-05-26 | 19.38x |
| 2026-05-22 | 19.41x |
| 2026-05-21 | 19.35x |
| 2026-05-20 | 19.23x |
| 2026-05-19 | 18.03x |
| 2026-05-18 | 17.54x |
| 2026-05-15 | 16.61x |
| 2026-05-14 | 15.60x |
| 2026-05-13 | 15.80x |
| 2026-05-12 | 16.48x |
| 2026-05-11 | 16.00x |
| 2026-05-08 | 16.34x |
| 2026-05-07 | 16.42x |
| 2026-05-06 | 16.28x |
| 2026-05-05 | 16.04x |
| 2026-05-04 | 16.19x |
| 2026-05-01 | 16.54x |
| 2026-04-30 | 16.06x |
| 2026-04-29 | 17.25x |
| 2026-04-28 | 17.77x |
| 2026-04-27 | 18.38x |
| 2026-04-24 | 18.43x |
| 2026-04-23 | 18.76x |
| 2026-04-22 | 18.97x |
| 2026-04-21 | 18.73x |
| 2026-04-20 | 19.32x |
| 2026-04-17 | 19.13x |
| 2026-04-16 | 18.33x |
| 2026-04-15 | 18.42x |
| 2026-04-14 | 18.83x |
| 2026-04-13 | 18.88x |
| 2026-04-10 | 19.15x |
| 2026-04-09 | 19.63x |
| 2026-04-08 | 19.67x |
| 2026-04-07 | 18.88x |
| 2026-04-06 | 18.91x |
| 2026-04-02 | 18.62x |
| 2026-04-01 | 18.66x |
| 2026-03-31 | 18.79x |
| 2026-03-30 | 18.52x |
| 2026-03-27 | 18.63x |
| 2026-03-26 | 19.75x |
| 2026-03-25 | 19.97x |
| 2026-03-24 | 19.90x |
| 2026-03-23 | 19.71x |
| 2026-03-20 | 20.01x |
| 2026-03-19 | 20.10x |
| 2026-03-18 | 20.21x |
| 2026-03-17 | 20.11x |
| 2026-03-16 | 19.83x |
| 2026-03-13 | 19.21x |
| 2026-03-12 | 19.51x |
| 2026-03-11 | 19.82x |
| 2026-03-10 | 20.25x |
| 2026-03-09 | 20.53x |
| 2026-03-06 | 20.34x |
| 2026-03-05 | 21.10x |
| 2026-03-04 | 21.75x |
| 2026-03-03 | 21.81x |
| 2026-03-02 | 22.01x |
| 2026-02-27 | 21.91x |
| 2026-02-26 | 22.19x |
| 2026-02-25 | 21.83x |
| 2026-02-24 | 21.81x |
| 2026-02-23 | 21.86x |
| 2026-02-20 | 21.81x |
| 2026-02-19 | 21.57x |
| 2026-02-18 | 21.72x |
| 2026-02-17 | 21.03x |
| 2026-02-13 | 20.91x |
| 2026-02-12 | 19.46x |
| 2026-02-11 | 23.32x |
| 2026-02-10 | 23.32x |
| 2026-02-09 | 23.99x |
| 2026-02-06 | 23.92x |
| 2026-02-05 | 23.90x |
| 2026-02-04 | 24.21x |
| 2026-02-03 | 24.48x |
| 2026-02-02 | 24.78x |
| 2026-01-30 | 24.95x |
| 2026-01-29 | 25.27x |
| 2026-01-28 | 25.05x |
| 2026-01-27 | 25.16x |
| 2026-01-26 | 25.05x |
| 2026-01-23 | 24.89x |
| 2026-01-22 | 25.24x |
| 2026-01-21 | 24.64x |
| 2026-01-20 | 24.18x |
| 2026-01-16 | 23.78x |
| 2026-01-15 | 23.68x |
| 2026-01-14 | 23.83x |
| 2026-01-13 | 24.02x |
| 2026-01-12 | 24.26x |
| 2026-01-09 | 23.07x |
| 2026-01-08 | 23.41x |
| 2026-01-07 | 23.97x |
| 2026-01-06 | 23.90x |
| 2026-01-05 | 23.15x |
| 2026-01-02 | 22.78x |
| 2025-12-31 | 22.72x |
| 2025-12-30 | 22.95x |
| 2025-12-29 | 23.09x |
| 2025-12-26 | 23.12x |
| 2025-12-24 | 23.07x |
| 2025-12-23 | 22.89x |
| 2025-12-22 | 23.08x |
| 2025-12-19 | 22.62x |
| 2025-12-18 | 22.57x |
| 2025-12-17 | 22.52x |
| 2025-12-16 | 22.72x |
| 2025-12-15 | 22.51x |
| 2025-12-12 | 22.92x |
| 2025-12-11 | 23.58x |
| 2025-12-10 | 23.12x |
| 2025-12-09 | 22.71x |
| 2025-12-08 | 22.48x |
| 2025-12-05 | 22.43x |
| 2025-12-04 | 22.35x |
| 2025-12-03 | 22.22x |
| 2025-12-02 | 22.09x |
| 2025-12-01 | 21.78x |
| 2025-11-28 | 21.76x |
| 2025-11-26 | 21.45x |
| 2025-11-25 | 21.17x |
| 2025-11-24 | 21.34x |
| 2025-11-21 | 20.68x |
| 2025-11-20 | 20.08x |
| 2025-11-19 | 20.51x |
| 2025-11-18 | 20.66x |
| 2025-11-17 | 20.10x |
| 2025-11-14 | 19.96x |
| 2025-11-13 | 20.51x |
| 2025-11-12 | 20.47x |
| 2025-11-11 | 19.98x |
| 2025-11-10 | 18.88x |
| 2025-11-07 | 18.94x |
| 2025-11-06 | 19.94x |
| 2025-11-05 | 20.36x |
| 2025-11-04 | 21.00x |
| 2025-11-03 | 20.75x |
| 2025-10-31 | 20.01x |
| 2025-10-30 | 23.33x |
| 2025-10-29 | 28.15x |
| 2025-10-28 | 28.56x |
| 2025-10-27 | 29.11x |
| 2025-10-24 | 28.99x |
| 2025-10-23 | 29.28x |
| 2025-10-22 | 29.14x |
| 2025-10-21 | 28.76x |
| 2025-10-20 | 28.25x |
| 2025-10-17 | 27.53x |
| 2025-10-16 | 27.42x |
| 2025-10-15 | 27.06x |
| 2025-10-14 | 27.37x |
| 2025-10-13 | 26.98x |
| 2025-10-10 | 26.95x |
| 2025-10-09 | 28.11x |
| 2025-10-08 | 27.99x |
| 2025-10-07 | 27.30x |
| 2025-10-06 | 27.43x |
| 2025-10-03 | 27.70x |
| 2025-10-02 | 27.46x |
| 2025-10-01 | 27.32x |
| 2025-09-30 | 27.80x |
| 2025-09-29 | 27.47x |
| 2025-09-26 | 27.72x |
| 2025-09-25 | 28.20x |
| 2025-09-24 | 27.88x |
| 2025-09-23 | 28.16x |
| 2025-09-22 | 28.67x |
| 2025-09-19 | 27.86x |
| 2025-09-18 | 31.13x |
| 2025-09-17 | 31.39x |
| 2025-09-16 | 31.44x |
| 2025-09-15 | 31.05x |
| 2025-09-12 | 31.31x |
| 2025-09-11 | 31.22x |
| 2025-09-10 | 31.22x |
| 2025-09-09 | 32.16x |
| 2025-09-08 | 32.01x |
| 2025-09-05 | 32.99x |
| 2025-09-04 | 33.09x |
| 2025-09-03 | 32.37x |
| 2025-09-02 | 30.55x |
| 2025-08-29 | 30.96x |
| 2025-08-28 | 30.86x |
| 2025-08-27 | 31.37x |
| 2025-08-26 | 31.27x |
| 2025-08-25 | 31.20x |
| 2025-08-22 | 33.68x |
| 2025-08-21 | 33.03x |
| 2025-08-20 | 33.45x |
| 2025-08-19 | 33.14x |
| 2025-08-18 | 33.11x |
| 2025-08-15 | 33.16x |
| 2025-08-14 | 32.78x |
| 2025-08-13 | 32.78x |
| 2025-08-12 | 32.86x |
| 2025-08-11 | 31.95x |
| 2025-08-08 | 32.34x |
| 2025-08-07 | 31.38x |
| 2025-08-06 | 31.38x |
| 2025-08-05 | 31.01x |
| 2025-08-04 | 31.32x |
| 2025-08-01 | 32.51x |
| 2025-07-31 | 33.09x |
| 2025-07-30 | 36.35x |
| 2025-07-29 | 39.06x |
| 2025-07-28 | 39.14x |
| 2025-07-25 | 38.91x |
| 2025-07-24 | 37.97x |
| 2025-07-23 | 37.84x |
| 2025-07-22 | 37.29x |
| 2025-07-21 | 36.84x |
| 2025-07-18 | 36.78x |
| 2025-07-17 | 36.87x |
| 2025-07-16 | 36.88x |
| 2025-07-15 | 37.15x |
| 2025-07-14 | 37.38x |
| 2025-07-11 | 36.56x |
| 2025-07-10 | 37.44x |
| 2025-07-09 | 37.19x |
| 2025-07-08 | 36.72x |
| 2025-07-07 | 36.38x |
| 2025-07-03 | 36.38x |
| 2025-07-02 | 36.65x |
| 2025-07-01 | 36.65x |
| 2025-06-30 | 38.20x |
| 2025-06-27 | 37.80x |
| 2025-06-26 | 37.26x |
| 2025-06-25 | 37.11x |
| 2025-06-24 | 38.32x |
| 2025-06-23 | 35.09x |
| 2025-06-20 | 35.15x |
| 2025-06-18 | 35.58x |
| 2025-06-17 | 35.92x |
| 2025-06-16 | 36.41x |
| 2025-06-13 | 35.99x |
| 2025-06-12 | 36.34x |
| 2025-06-11 | 36.40x |
| 2025-06-10 | 37.17x |
| 2025-06-09 | 37.53x |
| 2025-06-06 | 37.94x |
| 2025-06-05 | 37.55x |
| 2025-06-04 | 37.50x |
| 2025-06-03 | 37.99x |
| 2025-06-02 | 37.46x |
Showing the most recent 260 of 1,793 data points. The chart above shows the full history.
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach